Hologic (NASDAQ:HOLX) Issues Q1 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its first quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $1.00-1.03 for the period, compared to the consensus estimate of $1.03. The company issued revenue guidance of $1.025-1.035 billion, compared to the consensus revenue estimate of $1.04 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HOLX shares. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday. Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. Finally, Leerink Partners cut their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $1.03 during midday trading on Wednesday, hitting $79.83. The stock had a trading volume of 693,500 shares, compared to its average volume of 1,587,046. Hologic has a 1 year low of $66.93 and a 1 year high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The stock has a 50 day moving average price of $81.05 and a two-hundred day moving average price of $78.11. The company has a market capitalization of $18.54 billion, a PE ratio of 26.80, a P/E/G ratio of 2.98 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the company earned $0.89 EPS. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Hologic will post 4.09 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.